Brain aging is not uniform, and the factors that protect cortical architecture into later life remain incompletely understood. Emerging evidence positions cumulative ovarian hormone exposure as one such factor — yet most imaging research has examined menopause hormone therapy in isolation, leaving the long-arc influence of contraceptive use and reproductive timing largely unmapped. This analysis attempts to close that gap in a clinically meaningful population.
Drawing on baseline MRI data from 459 women aged 65–80 enrolled in the multi-site IGNITE aerobic exercise trial, researchers applied voxel-based morphometry (VBM) and surface-based morphometry (SBM) to quantify gray matter volume and cortical thickness. Women who had used hormonal birth control showed greater gray matter volume in temporal, occipital, and frontal regions compared to non-users. Longer duration of contraceptive use was specifically associated with larger fusiform gyrus volume — a region central to visual object and face recognition. Women with combined birth control and menopausal hormone therapy exposure demonstrated additional volumetric advantages in parietal and temporal areas alongside thicker cortex in the posterior cingulate and temporal gyri. Later onset of natural menopause, reflecting longer endogenous estrogen exposure, independently correlated with greater posterior cortical thickness. Notably, the timing of menopausal hormone therapy initiation did not emerge as a significant predictor.
This work is significant because it is among the first to model early-, mid-, and late-life hormonal exposures simultaneously in a neuroimaging cohort. The findings align with the "critical window" hypothesis in estrogen neurobiology — the idea that cumulative, sustained exposure across the lifespan may matter more than any single intervention window. That said, several limitations temper interpretation. Hormone use was measured via retrospective self-report, introducing recall bias. The cross-sectional baseline design precludes causal inference; women who used contraceptives longer may differ systematically on lifestyle, socioeconomic, and health variables. The cohort is also limited to women who enrolled in an exercise trial, potentially skewing toward healthier, more health-engaged individuals. Replication in prospective, population-representative samples with objective hormone assays would substantially strengthen these associations. Overall, the study is incremental but directionally important — repositioning contraceptive history as a neurologically relevant life-course variable worth tracking in dementia risk research.